Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Summary

The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered as monotherapy or in combination with an oral GnRH antagonist in the neoadjuvant setting.

Timeline

Start

2024-11-25

Primary completion

2027-01-22

Completion

2030-01-23

Drugs

Indications